GlassScriptPhysician profile
Vinay Vermani
NPI 1245264449
$4,969.16
in general payments reported to CMS, 2019-2025
43 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $391 · 2021: $669 · 2022: $911 · 2023: $704 · 2024: $669 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.84 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $582.50 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Amgen INC. | $519.19 | 2019-2023 | Lumakras, Blincyto |
| E.R. Squibb & Sons, L.L.C. | $503.29 | 2019-2024 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $461.62 | 2019-2024 | |
| Celgene Corporation | $369.58 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $252.56 | 2019-2025 | Keytruda, Lynparza |
| Shield Therapeutics INC | $244.42 | 2024 | |
| Genentech USA, INC. | $221.05 | 2019-2020 | |
| Daiichi Sankyo INC. | $184.11 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $162.23 | 2021-2025 | Ojjaara |
| Gilead Sciences, INC. | $155.54 | 2019-2025 | Trodelvy |
| Seagen INC. | $148.38 | 2019-2023 | Padcev, Tukysa |
| Pfizer INC. | $133.63 | 2019-2025 | |
| Genzyme Corporation | $110.43 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $102.40 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Vermani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.